Tomonori Ono1, Solomon L Moshé, Aristea S Galanopoulou. 1. Saul R. Korey Department of Neurology, Laboratory of Developmental Epilepsy, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Abstract
PURPOSE: Infantile spasms are the signature seizures of West syndrome. The conventional treatments for infantile spasms, such as adrenocorticotropic hormone (ACTH) and vigabatrin, are not always effective, especially in symptomatic infantile spasms (SIS). We tested the efficacy of carisbamate, a novel neurotherapeutic drug, to suppress spasms in the multiple-hit rat model of SIS, and compared it with phenytoin to determine if its effect is via sodium-channel blockade. METHODS: Sprague-Dawley rats received right intracerebral infusions of doxorubicin and lipopolysaccharide at postnatal day 3 (PN3) and intraperitoneal p-chlorophenylalanine at PN5. A single intraperitoneal injection of carisbamate was administered at PN4, after the onset of spasms, at the following doses: 10 mg/kg (CRS-10), 30 mg/kg (CRS-30), and 60 mg/kg (CRS-60), and was compared to vehicle-injected group (VEH). Video-monitoring of PN6-7 CRS-60 or VEH-injected pups was also done. KEY FINDINGS: Carisbamate acutely reduced both behavioral spasms (CRS-30 and CRS-60 groups only) and electroclinical spasms during the first 2-3 postinjection hours, without detectable toxicity or mortality. In contrast, phenytoin (20 or 50 mg/kg) failed to suppress spasms. SIGNIFICANCE: Our findings provide preclinical evidence that carisbamate displays acute anticonvulsive effect on spasms through a sodium channel-independent mechanism. Because spasms in the multiple-hit rat model are refractory to ACTH and transiently sensitive to vigabatrin, carisbamate may constitute a candidate new therapy for SIS, including the ACTH-refractory spasms. Further confirmation with clinical studies is needed. Wiley Periodicals, Inc.
PURPOSE:Infantile spasms are the signature seizures of West syndrome. The conventional treatments for infantile spasms, such as adrenocorticotropic hormone (ACTH) and vigabatrin, are not always effective, especially in symptomatic infantile spasms (SIS). We tested the efficacy of carisbamate, a novel neurotherapeutic drug, to suppress spasms in the multiple-hit rat model of SIS, and compared it with phenytoin to determine if its effect is via sodium-channel blockade. METHODS:Sprague-Dawley rats received right intracerebral infusions of doxorubicin and lipopolysaccharide at postnatal day 3 (PN3) and intraperitoneal p-chlorophenylalanine at PN5. A single intraperitoneal injection of carisbamate was administered at PN4, after the onset of spasms, at the following doses: 10 mg/kg (CRS-10), 30 mg/kg (CRS-30), and 60 mg/kg (CRS-60), and was compared to vehicle-injected group (VEH). Video-monitoring of PN6-7 CRS-60 or VEH-injected pups was also done. KEY FINDINGS:Carisbamate acutely reduced both behavioral spasms (CRS-30 and CRS-60 groups only) and electroclinical spasms during the first 2-3 postinjection hours, without detectable toxicity or mortality. In contrast, phenytoin (20 or 50 mg/kg) failed to suppress spasms. SIGNIFICANCE: Our findings provide preclinical evidence that carisbamate displays acute anticonvulsive effect on spasms through a sodium channel-independent mechanism. Because spasms in the multiple-hit rat model are refractory to ACTH and transiently sensitive to vigabatrin, carisbamate may constitute a candidate new therapy for SIS, including the ACTH-refractory spasms. Further confirmation with clinical studies is needed. Wiley Periodicals, Inc.
Authors: Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne Journal: Lancet Date: 2004 Nov 13-19 Impact factor: 79.321
Authors: Meir Bialer; Svein I Johannessen; René H Levy; Emilio Perucca; Torbjörn Tomson; H Steve White Journal: Epilepsy Res Date: 2010-12 Impact factor: 3.045
Authors: Suchean Chien; Meir Bialer; Bhavna Solanki; Tom Verhaeghe; Dennis R Doose; Gerald Novak; Caiping Yao Journal: Epilepsia Date: 2006-11 Impact factor: 5.864
Authors: M T Mackay; S K Weiss; T Adams-Webber; S Ashwal; D Stephens; K Ballaban-Gill; T Z Baram; M Duchowny; D Hirtz; J M Pellock; W D Shields; S Shinnar; E Wyllie; O C Snead Journal: Neurology Date: 2004-05-25 Impact factor: 9.910
Authors: Maureen G Price; Jong W Yoo; Daniel L Burgess; Fang Deng; Richard A Hrachovy; James D Frost; Jeffrey L Noebels Journal: J Neurosci Date: 2009-07-08 Impact factor: 6.167
Authors: Dorothée G A Kasteleijn-Nolst Trenité; Jacqueline A French; Edouard Hirsch; Jean-Paul Macher; Bernd-Ulrich Meyer; Pascal A Grosse; Bassel W Abou-Khalil; William E Rosenfeld; Joop van Gerven; Gerald P Novak; Lucio Parmeggiani; Bernd Schmidt; David Gibson; Renzo Guerrini Journal: Epilepsy Res Date: 2007-04-19 Impact factor: 3.045
Authors: Miguel A Cortez; Liqing Shen; Ying Wu; Ilyas S Aleem; Catherine H Trepanier; Hamid R Sadeghnia; Asim Ashraf; Ashlin Kanawaty; Chen-Chu Liu; Lee Stewart; O Carter Snead Journal: Pediatr Res Date: 2009-05 Impact factor: 3.756
Authors: Marine Jequier Gygax; Brian D Klein; H Steve White; Mimi Kim; Aristea S Galanopoulou Journal: Epilepsy Res Date: 2013-10-28 Impact factor: 3.045